FDA Approves Label Update to Include Additional Data for Otezla ® (apremilast)

Dr. Lyn Guenther, MD, FRCPC, Professor of Dermatology at Western University in London Ontario Canada discusses the FDA approval for a label update  for  Otezla ® (apremilast)  to include results from the Phase 3 DISCREET trial, which assessed the efficacy and safety of Otezla in patients with moderate-to-severe plaque psoriasis and with moderate-to-severe genital psoriasis (PsO).

Dr. Lyn Guenther is a Professor of Dermatology at Western University in London Ontario Canada, Fellow of the College of Physicians and Surgeons of Canada (FRCPC) and is Board-Certified in the United States. She received her MD degree from the University of Western Ontario and completed her dermatology residency training at the University of Michigan, Ann Arbor Michigan, USA. She has been involved in more than 160 research projects since 1980 and is the president of Guenther Research Inc.

Dr. Guenther was the President of the Canadian Society for Dermatologic Surgery from 2001 to 2003. She chaired the Canadian expert panel for the treatment of moderate-to-severe psoriasis in 2004, was a member of the expert panel for the 2009 and 2016 Canadian Psoriasis Guidelines. She was also a member of the 2015 Canadian Non-melanoma Skin Cancer Guidelines Committee.

Dr. Guenther has more than 200 publications, is a reviewer for a number of journals, and has been the medical editor of Dermatology Times of Canada since 1998. She has lectured to medical students at St. George’s University in Grenada and has acted as an advisor to Health Canada, the Drug Quality and Therapeutics Committee for Ontario, the Canadian Medical Protective Association, the Canadian Cancer Society, and many pharmaceutical companies.

Dr. Guenther enjoys teaching and lectures locally, provincially, nationally and internationally. She has won a certificate of appreciation for excellence in undergraduate medical education and since 2007, has been voted “Best Doctor” by peers.